SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-05721

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-05721
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

SARS-CoV-2

Applications

ELISA, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Human IgG Clone # N009

Format

BSA Free

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all SARS-CoV-2 Nucleocapsid Antibodies »

Product Specifications

Immunogen

SARS-CoV-2 Nucleocapsid recombinant protein

Clonality

Monoclonal

Host

Human

Isotype

IgG

Scientific Data Images for SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free

Western Blot: SARS-CoV-2 Nucleocapsid Antibody (N009)BSA Free [NBP3-05721]

Western Blot: SARS-CoV-2 Nucleocapsid Antibody (N009)BSA Free [NBP3-05721]

Western Blot: SARS-CoV-2 Nucleocapsid Antibody (N009) [NBP3-05721] - Western Blot Validation with Recombinant Protein. Loading: 1ug of SARS-CoV-2 (COVID-19) nucleocapsid recombinant protein per lane. Antibodies: SARS-CoV-2 Nucleocapsid Antibody, NBP3-05721, 1:2000. Secondary: Goat anti-human IgG HRP conjugate at 1:5000 dilution.
ELISA: SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free [NBP3-05721]

ELISA: SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free [NBP3-05721]

ELISA: SARS-CoV-2 Nucleocapsid Antibody (N009) [NBP3-05721] - ELISA Coating original concentration: 2 ug/mL, 100 uL/well sample is SARS-CoV-2 Nucleocapsid Recombinant Protein, 100 uL/well. Stop buffer 50 uL/well.

Applications for SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free

Application
Recommended Usage

ELISA

1:320000

Western Blot

1:2000-3000

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS, 10% glycerol, pH 7.2

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: SARS-CoV-2 Nucleocapsid

The SARS-CoV-2 Nucleocapsid protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The nucleocapsid protein is an RNA-binding protein that is essential for viral assembly into a ribonucleoprotein complex and also functions in viral budding (2,3). More specifically, after viral replication and RNA synthesis, the viral genomes that are encapsulated by the nucleocapsid protein will bud into the membrane and help with mature virus formation (2). The nucleocapsid protein is synthesized as 419 amino acids (aa) in length with a theoretical molecular weight of 45.6 kDa (4). Structurally, the nucleocapsid protein contains an RNA-binding domain (N1b), a dimerization domain (N2b), and a few shorter regions (N1a, N2a, and spacer B/N3) (3). It is the N1b domain that is suggested to be involved in RNA binding (3). The nucleocapsid N1b domain contains a beta-hairpin, a loop region, and a beta-sheet core, giving it a right-handed shape (3). Conversely, the N2b domain functions in dimerization which promotes assembly into a helical filament where the dimer interface is made of two beta-strands and an alpha-helix portion (3). Inhibition of nucleocapsid assembly may be a potential target for treating COVID-19 infection.

Following SARS-CoV-2 infection, B cells and T cells display an immune response against nucleocapsid protein and nucleocapsid-specific neutralizing antibodies are produced (5). Interestingly, a study of patients who have recovered from COVID-19 revealed that there were no neutralizing antibodies against nucleocapsid protein present; however, a high presence against neutralizing spike RBD antibodies were detected (5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. https://doi.org/10.1016/j.crmicr.2020.06.003

4. Uniprot (P0DTC9)

5. Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01949

Alternate Names

2019-nCoV N Protein, 2019-nCoV Nucleocapsid Protein, COVID-19 N protein, COVID-19 nucleocapsid protein, Human coronavirus Nucleoprotein, nucleocapsid phosphoprotein, Nucleocapsid protein, Nucleoprotein, ORF9; structural protein, SARS-CoV-2, SARS-CoV-2 Nucleocapsid protein, SARS-CoV-2 N protein, SARSCoV2 Nucleoprotein, Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein

Gene Symbol

N

Additional SARS-CoV-2 Nucleocapsid Products

Product Documents for SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for SARS-CoV-2 Nucleocapsid Antibody (N009) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.